BR112017004882A2 - composição farmacêutica oral. - Google Patents

composição farmacêutica oral.

Info

Publication number
BR112017004882A2
BR112017004882A2 BR112017004882-5A BR112017004882A BR112017004882A2 BR 112017004882 A2 BR112017004882 A2 BR 112017004882A2 BR 112017004882 A BR112017004882 A BR 112017004882A BR 112017004882 A2 BR112017004882 A2 BR 112017004882A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
oral pharmaceutical
oral
composition
pharmaceutical
Prior art date
Application number
BR112017004882-5A
Other languages
English (en)
Other versions
BR112017004882B1 (pt
Inventor
Gurvinder Singh Rekhi
Richard Sidwell
Original Assignee
Recro Gainesville Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54063391&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112017004882(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Recro Gainesville Llc filed Critical Recro Gainesville Llc
Publication of BR112017004882A2 publication Critical patent/BR112017004882A2/pt
Publication of BR112017004882B1 publication Critical patent/BR112017004882B1/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1635Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1641Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
BR112017004882-5A 2014-09-12 2015-09-11 Composições farmacêuticas resistentes ao uso excessivo BR112017004882B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14/484,761 US9132096B1 (en) 2014-09-12 2014-09-12 Abuse resistant pharmaceutical compositions
US14/484,761 2014-09-12
PCT/IB2015/056993 WO2016038584A1 (en) 2014-09-12 2015-09-11 Abuse resistant pharmaceutical compositions

Publications (2)

Publication Number Publication Date
BR112017004882A2 true BR112017004882A2 (pt) 2018-11-06
BR112017004882B1 BR112017004882B1 (pt) 2023-06-20

Family

ID=

Also Published As

Publication number Publication date
RU2017112301A (ru) 2018-10-12
US9713611B2 (en) 2017-07-25
CN107106503B (zh) 2020-08-14
US20160279062A1 (en) 2016-09-29
CA2870380C (en) 2022-05-10
US9452163B2 (en) 2016-09-27
JP2017527629A (ja) 2017-09-21
US10960000B2 (en) 2021-03-30
RS62056B1 (sr) 2021-07-30
JP6929407B2 (ja) 2021-09-01
EP3191085B1 (en) 2021-03-24
PL3191085T3 (pl) 2021-10-25
HUE054778T2 (hu) 2021-09-28
CN111632041B (zh) 2022-10-04
SI3191085T1 (sl) 2021-08-31
SG11201701845XA (en) 2017-05-30
CN111632041A (zh) 2020-09-08
US9486451B2 (en) 2016-11-08
CA2870380A1 (en) 2016-03-12
PT3191085T (pt) 2021-06-22
CY1124757T1 (el) 2022-07-22
IL251011B (en) 2018-05-31
LT3191085T (lt) 2021-07-12
JP2020114855A (ja) 2020-07-30
AU2015313785B2 (en) 2020-03-19
RU2764569C2 (ru) 2022-01-18
AU2020203841B2 (en) 2021-07-08
CN107106503A (zh) 2017-08-29
US10092559B2 (en) 2018-10-09
US20160074385A1 (en) 2016-03-17
US20190167663A1 (en) 2019-06-06
US20160074386A1 (en) 2016-03-17
EP3191085A1 (en) 2017-07-19
NZ730882A (en) 2023-08-25
HRP20210973T1 (hr) 2021-09-17
AU2015313785A1 (en) 2017-04-27
US20170319576A1 (en) 2017-11-09
MX2017003082A (es) 2017-07-24
RU2017112301A3 (pt) 2019-04-17
DK3191085T3 (da) 2021-06-28
US9132096B1 (en) 2015-09-15
IL251011A0 (en) 2017-04-30
WO2016038584A1 (en) 2016-03-17
ES2877058T3 (es) 2021-11-16
JP6687624B2 (ja) 2020-04-22
CR20170142A (es) 2017-08-22
AU2020203841A1 (en) 2020-07-02

Similar Documents

Publication Publication Date Title
BR112016023628A2 (pt) composições farmacêuticas.
DK3529248T3 (da) Farmaceutiske sammensætninger
DK3089741T3 (da) Farmaceutiske sammensætninger omfattende azd9291
DK3297605T3 (da) Topiske, farmaceutiske sammesætninger
GB201409471D0 (en) Pharmaceutical composition
DK3199161T3 (da) Farmaceutisk præparat
GB201409485D0 (en) Pharmaceutical composition
GB201409488D0 (en) Pharmaceutical composition
DK3223796T3 (da) Farmaceutiske sammensætninger, fremstilling og anvendelser deraf
DK3191085T3 (da) Misbrugsresistente farmaceutiske sammensætninger
DK3157506T3 (da) Smagsmaskeret oral, farmaceutisk sammensætning
DK3280447T3 (da) Farmaceutiske formuleringer
DK3313370T3 (da) Oftalmologisk farmaceutisk sammensætning
KR20180084728A (ko) 구강용 조성물
DK3288967T3 (da) Farmaceutisk forbindelse
DK3256138T3 (da) Farmaceutiske sammensætninger omfattende meloxicam
DK3089740T3 (da) Farmaceutisk sammensætning
DK2915526T3 (da) Farmaceutiske sammensætninger, der omfatter anagrelid
DK3424500T3 (da) Farmaceutisk sammensætning, der omfatter famitinib
SG10201504332VA (en) Pharmaceutical Composition
BR112016028542A2 (pt) implemento de cuidado oral.
DK3288966T3 (da) Farmaceutisk forbindelse
TH1601003393A (th) รูปแบบปริมาณที่ให้ทางเภสัชกรรม
TH1501007601A (th) ส่วนผสมสำหรับใช้ในช่องปาก
TH1501006784A (th) องค์ประกอบทางเภสัชกรรมขนาดยาต่ำ

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO POR NAO SE ENQUADRAR NO ART. 229-C DA LPI (NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021).

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 11/09/2015, OBSERVADAS AS CONDICOES LEGAIS